

REMARKS

The specification has been amended to correct an obvious inadvertently introduced typographical error. Support for this amendment is inherently provided by the originally filed specification and sequence listing (See e.g., specification at page 21, lines 5, 15 and 18, and SEQ ID NOS: 33 and 43, for the recitation of “Abu”). As is immediately recognized by those of ordinary skill in the art, “Abu” as recited in the specification and sequence listing, refers to “ $\alpha$ -aminobutyric acid” (See e.g., MPEP § 2422, Table 4 and PatentIn 3.5 User Manual, Appendix F, Table F-2, copies of the relevant pages of which are enclosed for the Examiner’s convenience). It is believed that no new matter has been introduced by the amendment to the specification.

In view of the foregoing, Applicants respectfully submit that the present application is in compliance with 37 C.F.R. §§ 1.821-1.825. Therefore, withdrawal of the Notification to Comply with Requirements is respectfully requested.

Respectfully submitted,

OBLON, SPIVAK, McCLELLAND,  
MAIER & NEUSTADT, L.L.P.



Vincent K. Shier, Ph.D.  
Attorney of Record  
Registration No. 50,552

David P. Stitzel  
Attorney of Record  
Registration No. 44,360

Customer Number  
**22850**

Tel: (703) 413-3000  
Fax: (703) 413 -2220  
(OSMMN 07/09)